Skip to main content

Table 2 Results of univariable and multivariable Cox regression models for overall survival

From: Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

  N Median OS Univariable Multivariable
Hazard ratio p value Hazard ratio p value
Age (years)      0.260   
Gender      0.712   
BMI      0.122   
ASA 2 15 12.2 (5.8-14.4)   0.037 0.170 (-0.299-0.638) 0.4730
3 17 18.2 (15.5-27.9)
Synchronous PC      0.999   
Neo-adjuvant chemotherapy No 2 8.6 (3-14.2)   0.054 0.443 (-0.562-1.281) 0.3459
Yes 30 17 (12.5-24.9)
Duration of surgery (minutes)      0.444   
Intra-operative blood loss (ml)      0.619   
Total PCI score     0.114 (0.018-0.212) 0.020 0.750 (0.180-1.344) 0.0104
Number of regions involved PC     0.167 (0.005-0.340) 0.042 1.290 (0.434-2.246) 0.0029
Small bowel PCI score      0.1511   
Non-small bowel PCI score      0.068 0.564 (0.088-1.226) 0.0888
PC on small bowel No 8 28.6 (14-36.6)   0.098 0.545 (0.195-1.268) 0.1453
Yes 24 14.3 (9.2-18.2)
Number of small bowel regions involved PC      0.497   
Number of non-small bowel regions involved PC      0.078 0.910 (0.118-2.008) 0.0831
PC on any small bowel region with 4 or more non-small bowel regions No 20 24.7 (15.6-29.4)   <0.0001 1.383 (0.624-2.177) 0.0004
Yes 12 10.5 (5.8-14.2)
Adjuvant chemotherapy      0.821   
Postoperative complications      0.502   
  1. 95% confidence intervals are mention between parentheses; OS times are mentioned in months
  2. ASA American society of anesthesiology, BMI body mass index, ml milliliters, N number, OS overall survival, PC peritoneal carcinomatosis, PCI peritoneal carcinomatosis index
  3. Independent predictors of OS were PC on the small bowel combined with PC on 4 or more non-small bowel regions (p = 0.0004), number of regions involved (p = 0.0029), and overall PCI score (p = 0.0104)